In September, Zhongguancun announcement that due to the transformation and upgrading of the national economic structure, macro economic environment changes, the existing business growth is greatly restricted, the board of directors proposed to the pharmaceutical industry as the core of building the company's future business, and as the company's future strategic industry development direction.

The board of directors of the board of Directors believes that in vitro diagnostics industry, specialist hospitals and health care industry has important market opportunities. The company will focus on the pharmaceutical industry with huge market development space in vitro diagnostics as a representative of the new medical equipment, with high growth potential of specialist hospitals and the "light assets" of the health care management and some of the larger market opportunities prescription drugs and OTC product segments, through acquisitions, independent construction, increasing investment in research and development, the establishment of industrial mergers and acquisitions fund and other ways to expand business scale, as soon as possible to achieve a breakthrough, so that the company's business industry chain can quickly expand to create a new industry layout.

At the same time, the company will actively promote the reform of the existing pharmaceutical business innovation, through the implementation of internal settlement, the introduction of business partner system, the establishment of category alliance, to fully tap the sales potential of existing products, increase R & D investment, and steadily improve product quality and other strategic measures to enhance the scale of existing pharmaceutical business.

Companies strive to the short time of the pharmaceutical business to build a strategic leading industry, in the next three to five years to become the company's most profitable core business. By 2019, and strive to achieve the medical and pharmaceutical sectors of non pharmaceutical income scale than the size of the strategic objectives of the medical income.